The lawsuit, filed by the Rosen Law Firm, claims that Beta Bionics provided false assurances to the market about its automated insulin delivery system. According to the complaint, the company downplayed serious FDA concerns, labeling reports of device malfunctions as benign. In reality, the FDA had documented thousands of issues, including hundreds of life-threatening hypoglycemic events caused by dangerously high insulin doses.

Plaintiffs allege that Beta Bionics failed to implement necessary corrective actions following FDA scrutiny, misleading investors about the gravity of the product's defects. When these details surfaced, the company's stock value suffered, leading to the current legal challenge. Investors interested in participating in the class action or seeking appointment as lead plaintiff must move the court by the November 3 deadline.